Detail akcie Cipher online

Business Summary: Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Cipher Pharmaceuticals Inc revenues increased 77% to $38.2M. Net income increased 71% to $14M. Revenues reflect United States segment increase from $10.8M to $25.5M, Canada segment increase of 18% to $12.7M. Net income was partially offset by Depreciation and amortization increase from $2.5M to $5.4M (expense), Employee compensation increase from $2.5M to $5.1M (expense).